Once you decide you would like to work with Tempus, contact us at firstname.lastname@example.org and we will send you appropriate manuals, forms, and specimen collection kits based on your specific needs and requirements.
A test can be ordered by faxing a completed requisition form to us at 800.893.0276.
Our labs sequence both DNA and RNA from tumor samples as well as matched DNA from normal samples. Sequencing options include a targeted panel of 648 genes (at 500x coverage), whole exome (at 150x coverage), and whole genome (at 30x coverage).
Yes, the lab is CLIA-certified and CAP-accredited.
Tempus requires your patient’s tumor and blood or saliva specimens for DNA and RNA next generation sequencing. For more information, please review our specimen guidelines, which are available here. Tempus handles obtaining the tumor specimen.
Somatic sequencing using formalin-fixed or fresh-frozen samples to identify genomic aberrations in cancer malignancies. All sequencing data will be available for analysis, and all potentially relevant therapies are reported and prioritized based on the strength of the clinical evidence that establishes the association between a given genomic alteration and a relevant therapeutic option. RNA sequencing using tumor samples to analyze actionable genomic aberrations (e.g. gene fusions), gene expression analysis, rare and novel transcript discovery, and splice variant detection.
Tempus reports on all relevant therapeutic indications for detected somatic or gene expression alterations for which there is clinical evidence linking a given alteration to any FDA approved therapy in the cancer under study, or another cancer, and for alterations associated with a known or suspected contraindication to a given therapy. The first page summarizes the most relevant therapies with potential benefit and potential lack of benefit. Relevant therapies are prioritized based on the strength of the clinical evidence that establishes the association between a given genomic alteration and a relevant therapeutic option. The report cites all of the references for the clinical evidence that establishes the association between each genomic alteration and its matching therapy and additionally provides a complete bibliography of published research relevant to the targeted biomarkers and therapies. The clinical trials section matches your patient to eligible biomarker-based clinical trials.
Tempus uses capture RNA-seq to assess gene rearrangements and RNA expression levels from clinical FFPE tissue samples. This method is based on techniques published by Tempus scientific advisor Arul Chinnaiyan: “Through validation against gold-standard poly(A) and Ribo-Zero libraries from intact RNA, we show that capture RNA-seq provides accurate and unbiased estimates of RNA abundance, uniform transcript coverage, and broad dynamic range. Unlike poly(A) selection and Ribo-Zero depletion, capture libraries retain these qualities regardless of RNA quality and provide excellent data from clinical specimens including formalin-fixed paraffin-embedded (FFPE) blocks.”
A PDF of the summary section of the report will be emailed to you. In addition, when your first Tempus report is complete, you will receive an email with your unique login information. Once the report is complete, you will be able to login to access your patientʼs detailed report, including both the clinical and research sections.
If you lose or forget your password for portal login, navigate to clinical-portal.securetempus.com and click on the “Forgot Password” button. A temporary password will be sent to your email account. You will then be prompted to create a new unique password.
Please try the patientʼs first name last name, or MRN. The name is not case sensitive. If the record does not load within one minute, please email us at email@example.com.
You can navigate to historic orders and reports by searching by patient name or MRN in the top search bar.
Tempus results can be expected 9-14 days after samples are received (both blood and tissue). Sequencing will not begin until all required specimens are received.
Yes, we work with many academic institutions and principal investigators on research projects pertaining to genomic sequencing of cancer patients. Please email firstname.lastname@example.org to get started.
Please call our Customer Support Team at 800.739.4137 or email email@example.com.